재택 주입 요법 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 지역별, 부문 예측(2025-2030년)

Home Infusion Therapy Market Summary

The global home infusion therapy market was valued at USD 38.66 billion in 2024 and is expected to reach USD 61.72 billion by 2030, growing at a CAGR of 8.2% from 2025 to 2030. Home infusion therapy involves delivering treatments, medications, or fluids directly into a patient's bloodstream through intravenous (IV) infusion, usually in the comfort and convenience of their home.

The market's growth is driven by several key factors, including the expanding geriatric population characterized by decreased mobility, a rising preference for home care, and the swift evolution of technological advancements. Infusion therapy, encompassing essential components like IV therapy and IV hydration therapy, plays a crucial role in addressing conditions such as immune deficiencies, cancer, and congestive heart failure, where oral medication is not a viable treatment option. The increasing demand for these therapies stems from the need for long-term treatment among patients, positioning home infusion therapy as a notably cost-effective alternative to hospital-based care. Incorporating IV therapy and IV hydration therapy serves as a driving force, providing patients with enhanced accessibility to effective and personalized medical solutions in the comfort of their homes.

The cost-effectiveness of home infusion therapy is a major factor driving its adoption across global healthcare systems. Enabling IV treatments outside hospital settings significantly reduces expenses associated with inpatient care, including hospital admissions, re-admissions, and extended stays. This model lowers direct treatment costs and minimizes ancillary expenditures such as facility overhead and staffing. Home infusion therapy offers substantial cost savings compared to traditional inpatient care, making it an attractive option for patients and healthcare payers. For instance,according to the National Home Infusion Association (NHIA), home infusion therapy costs approximately USD 122 to USD 225 per day. In contrast, inpatient care can range from USD 586 to USD 798 per day, depending on the therapy administered.

The increasing demographic of baby boomers struggling with diminished mobility due to conditions such as paralysis, osteoarthritis, and diabetes is expected to amplify the demand for home infusion therapy. The growing imperative to reduce the duration of inpatient stays is a pivotal factor poised to contribute significantly to the market's growth. Remarkably, continuous subcutaneous (SC) apomorphine infusion emerges as an exceptionally effective treatment for Parkinson's disease (PD), with diverse drug formulations available for the management of PD through subcutaneous delivery. In response to the mounting burden of PD, there is a notable surge in the demand for subcutaneous infusion therapy. For instance, in line with the Parkinson's Foundation's 2022 data update, approximately 90,000 individuals receive a PD diagnosis annually in the U.S. Furthermore, the anticipated number of people living with PD in the country is projected to soar to nearly 1.2 million by the year 2030.

Global Home Infusion Therapy Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels as well as provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the home infusion therapy market report on the basis of type, application, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Product
  • Infusion Pumps
  • Elastomeric
  • Electromechanical
  • Gravity
  • Others
  • Intravenous Sets
  • IV Cannulas
  • Needleless Connectors
• Services
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Anti-Infective
• Endocrinology
  • Diabetes
  • Others
• Hydration Therapy
  • Athlete
  • Others
• Chemotherapy
• Enteral Nutrition
• Parenteral Nutrition
• Specialty Pharmaceuticals
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Switzerland
  • Russia
  • Sweden
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Malaysia
  • Singapore
  • Thailand
  • Philippines
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Rest of Latin America
• Middle East & Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Egypt
  • Rest of Middle East & Africa (MEA)

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type Outlook
  • 2.2.2. Application Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Home Infusion Therapy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Home Infusion Therapy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Home Infusion Therapy Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. Home Infusion Therapy Market: Type Movement Analysis
• 4.3. Global Home Infusion Therapy Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Million)
• 4.4. Product
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Infusion Pumps
    • 4.4.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Elastomeric
    • 4.4.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Electromechanical
    • 4.4.4.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Gravity
    • 4.4.5.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.7. Intravenous Sets
    • 4.4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.8. IV Cannulas
    • 4.4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.9. Needleless Connectors
• 4.5. Services
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Home Infusion Therapy Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Home Infusion Therapy Market: Application Movement Analysis
• 5.3. Global Home Infusion Therapy Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Anti-Infective
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Endocrinology
  • 5.5.1. Diabetes
    • 5.5.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Others
    • 5.5.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.3. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.6. Hydration Therapy
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Athlete
    • 5.6.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.3. Others
    • 5.6.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.7. Chemotherapy
  • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.8. Enteral Nutrition
  • 5.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.9. Parenteral Nutrition
  • 5.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.10. Specialty Pharmaceuticals
  • 5.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.11. Others
  • 5.11.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Home Infusion Therapy Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Continuous Bioprocessing Market By Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S.
    • 6.4.1.1. Key Country Dynamics
    • 6.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.1.3. Competitive Scenario
    • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Canada
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.2.3. Competitive Scenario
    • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Mexico
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.3.3. Competitive Scenario
    • 6.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. UK
    • 6.5.1.1. Key Country Dynamics
    • 6.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.1.3. Competitive Scenario
    • 6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Germany
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.2.3. Competitive Scenario
    • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.5.3. Competitive Scenario
    • 6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Netherlands
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.6.3. Competitive Scenario
    • 6.5.6.4. Netherlands Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Belgium
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.7.3. Competitive Scenario
    • 6.5.7.4. Belgium Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.8. Switzerland
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.8.3. Competitive Scenario
    • 6.5.8.4. Switzerland Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.9. Russia
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.9.3. Competitive Scenario
    • 6.5.9.4. Russia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.10. Sweden
    • 6.5.10.1. Key Country Dynamics
    • 6.5.10.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.10.3. Competitive Scenario
    • 6.5.10.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key Country Dynamics
    • 6.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.1.3. Competitive Scenario
    • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.2.3. Competitive Scenario
    • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.3.3. Competitive Scenario
    • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.4. South Korea
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.4.3. Competitive Scenario
    • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.5.3. Competitive Scenario
    • 6.6.5.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Indonesia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.6.3. Competitive Scenario
    • 6.6.6.4. Indonesia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Malaysia
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.7.3. Competitive Scenario
    • 6.6.7.4. Malaysia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Singapore
    • 6.6.8.1. Key Country Dynamics
    • 6.6.8.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.8.3. Competitive Scenario
    • 6.6.8.4. Singapore Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.9. Thailand
    • 6.6.9.1. Key Country Dynamics
    • 6.6.9.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.9.3. Competitive Scenario
    • 6.6.9.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.10. Philippines
    • 6.6.10.1. Key Country Dynamics
    • 6.6.10.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.10.3. Competitive Scenario
    • 6.6.10.4. Philippines Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1.1. Key Country Dynamics
  • 6.7.1.2. Regulatory Framework/ Reimbursement Structure
  • 6.7.1.3. Competitive Scenario
  • 6.7.1.4. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.2.3. Competitive Scenario
    • 6.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.3.3. Competitive Scenario
    • 6.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Colombia
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.4.3. Competitive Scenario
    • 6.7.4.4. Colombia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.5. Chile
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.5.3. Competitive Scenario
    • 6.7.5.4. Chile Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.8. Middle East & Africa (MEA)
  • 6.8.1.1. Key Country Dynamics
  • 6.8.1.2. Regulatory Framework/ Reimbursement Structure
  • 6.8.1.3. Competitive Scenario
  • 6.8.1.4. Middle East & Africa (MEA)Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.2.3. Competitive Scenario
    • 6.8.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.3. South Africa
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.3.3. Competitive Scenario
    • 6.8.3.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.4. South Arabia
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.4.3. Competitive Scenario
    • 6.8.4.4. South Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.5. UAE
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.5.3. Competitive Scenario
    • 6.8.5.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.6. Israel
    • 6.8.6.1. Key Country Dynamics
    • 6.8.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.6.3. Competitive Scenario
    • 6.8.6.4. Israel Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.7. Egypt
    • 6.8.7.1. Key Country Dynamics
    • 6.8.7.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.7.3. Competitive Scenario
    • 6.8.7.4. Egypt Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key Company Heat Map Analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Baxter
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Type Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. B. Braun SE
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Type Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. BD
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Type Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Fresenius Kabi AG
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Type Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. ICU Medical, Inc.
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Type Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. Terumo Corporation
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Type Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. JMS Co. Ltd.
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Type Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. Option Care Health, Inc.
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Type Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. CareCentrix, Inc.
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Type Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Coram LLC.
    • 7.4.10.1. Company Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Type Benchmarking
    • 7.4.10.4. Strategic Initiatives
  • 7.4.11. PharMerica Corporation
    • 7.4.11.1. Company Overview
    • 7.4.11.2. Financial Performance
    • 7.4.11.3. Type Benchmarking
    • 7.4.11.4. Strategic Initiatives
  • 7.4.12. Moog Inc.
    • 7.4.12.1. Company Overview
    • 7.4.12.2. Financial Performance
    • 7.4.12.3. Type Benchmarking
    • 7.4.12.4. Strategic Initiatives
  • 7.4.13. Amedisys, Inc.
    • 7.4.13.1. Company Overview
    • 7.4.13.2. Financial Performance
    • 7.4.13.3. Type Benchmarking
    • 7.4.13.4. Strategic Initiatives